{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 39,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 21,
  "notes": "The chart is a swimmer plot, commonly used in oncology clinical trials to visualize time-to-event data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/22",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.65,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Swimmer plot of treatment duration by patient",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea38c957-350b-47d8-8f7e-97026d2db0c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.07,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a0e85fd-1f07-413f-a05f-937676ace3a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.22,
        "x": 0.71,
        "y": 0.36
      },
      "kind": "legend",
      "text": "Legend for treatment types, response status, and ongoing status",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ed193d0-0318-4785-93ec-4e85dfafc61b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.43,
        "y": 0.64
      },
      "kind": "list",
      "text": "76% (16/21) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.6 (1.0, 8.3+) months; No treatment discontinuation due to toxicity; Median (range) time to response: 3.6 (3.1, 4.6) weeks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d245d189-ef34-488d-8a32-82347f1e31f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Time on Treatment | Sustained Duration with Follow-up Ongoing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a9b50c6-3748-4377-92ae-dc0daec8b311",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 13,
      "beatId": "38e371b8-b1f4-4700-814e-96d0791c56bb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document showcases preclinical and clinical data for NVL-520 and NVL-655.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fe9c6514-22f1-4979-9b36-391b44fa3c8a",
      "evidence": "The document presents the limitations of current therapies and the potential benefits of Nuvalent's targeted therapies.",
      "position": 0,
      "objective": "The cost of inaction in addressing kinase resistance and selectivity challenges",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "2038f58a-de52-4ce2-87cd-b26435c6bd24",
      "evidence": "The document showcases preclinical and clinical data for NVL-520 and NVL-655.",
      "position": 1,
      "objective": "The potential for quick wins with Nuvalent's targeted therapies",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}